Speaker Profile

Ph.D., Executive Director, Precision Medicine, The Christ Hospital Health Network

Dr. Blaxall leads efforts to transition from reactive to proactive healthcare delivery by harnessing the power of personal diagnostic and genomic data. Using approaches ranging from cutting edge hereditary disease risk assessment, genetic counseling and testing to pharmacogenomics and genome-guided clinical care pathways, the Precision Medicine team he leads aims to provide proactive, individualized care for every patient. Dr. Blaxall holds several patents, has published nearly 100 peer-reviewed manuscripts and has received numerous local, national and international honors. He has held extensive national and international leadership positions in numerous academic and professional societies, chaired NIH peer-review panels and serves on the editorial board for numerous top professional journals. He is an elected fellow of several professional organizations (ACC, AHA, ISHR, APS) and currently serves in national leadership positions for prominent professional societies in the fields of Precision Medicine and Pharmacogenomics.

Implementing Pharmacogenomics in a Community Hospital: Lessons Learned
Non-optimized medication costs over double the expense of caring for any major disease. Comprehensive pharmacogenomics can dramatically reduce non-optimized medication and improve patient outcomes. Learn how Dr. Blaxall has implemented a broad program of comprehensive pharmacogenomics, coupled with complete EMR integration, across a health network in under two years.

 Session Abstract – PMWC 2022 Silicon Valley

Track Chairs:
Philip Empey, UPitt
Stuart Scott, Stanford

Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.

  • Keynote: The Future Of PGx
    - Julie Johnson, University of Florida
  • Payment and Policy Landscape for PGx
    - Sara Rogers, American Society of Pharmacovigilance
  • PGx Research and Discovery
    - Todd Skaar, Indiana University
  • PGx Innovative Industry Solutions
    - Jeffrey A. Shaman, Coriell Life Sciences
    - Cassie Hajek, Helix
    - Gillian Bell, Genome Medical
    - Cindy Kosinski, 23andme
  • Key Resources for PGx
    - Kelly E. Caudle, St. Jude Children’s Research Hospital
    - Michelle Whirl-Carillo, Stanford
  • Clinical Laboratory PGx Considerations
    - Ulrich Broeckel, MCW
    - Stuart Scott, Stanford
    - Victoria Pratt, Optum Genomics
  • Lessons from Frontline PGx Clinical Services
    - Mark H. Dunnenberger, Northshore University HealthSystem
    - Lucas Berenbrok, UPitt
    - Sony Tuteja, UPenn
    - Burns Blaxall, The Christ Hospital Health Network
  • Translational PGx Implementation Programs
    - Philip Empey, UPitt
    - Julie A. Johnson, Uinversity of Florida
    - Laura Ramsey, Cincinnati Children's Hospital
    - Nita A. Limdi, UAB
  • PMWC Showcase
    - Jose Estabil, Cipherome